Manama, AGU: The “Molecular Medicines Reports” journal published in January 2021 the results of a study conducted by the Medical Biotechnology Research Team in the College of Graduate Studies at Arabian Gulf University that included the discovery of the role played by the molecular compound known as ERP72, which is found in cells that cover blood vessels.

Prof. Dr. Mohammed-Dahmani Fathallah, who led the research team consisting of Dr. Noor Aldin Ben Khalaf and student Dalal Al-Muhatab, stated that the importance of this discovery lies primarily in that it came in the field of inflammation, which has been the main research area of the medical biotechnology program for more than a decade. Indeed inflammation is one of the most important biological processes of the immune system, which helps in repairing wounds or tissue damage or fighting diseases. However, if the immune cells lose control of the level of inflammation, the process becomes exacerbated causing many serious diseases and complications such as diabetes, heart disease, cancer, nerve diseases and even the COVID syndrome, which is currently sweeping the world.

Many of these inflammations are treated with anti-inflammatory drugs that prevent excessive infections from destroying healthy tissues in the body. Although most of these important drugs are readily available, many of their uses are specified/limited because the development of most of these drugs has not been based on accurate scientific information at the molecular level regarding the relationship of these drugs to the etiology of inflammation.   In this context and after discovering that the ERP72 molecule is a new sign of inflammation, the study focused on providing scientific information that demonstrated that this marker could be a target to develop drugs to treat inflammations. The study revealed that when specific antibodies are used to disable ERP72 molecule function, the inflammation level decreases significantly. This outcome is considered a scientific achievement and a firm step that opens the horizon for the development of the fourth generation of drugs that treat infections. Professor M. Dahmani Fathallah also added that the research team is moving forward towards this direction. He stated that the research and development processes takes time and that the right scientific environment whereby collaboration, logistical and financial support are available make the greatest elements of success. He also valued the participation of a doctoral student in such studies and the important role that young researchers play in establishing a culture of research and development that can be crowned with innovation. From another perspective, Prof.  Mohamed-Dahmani Fathallah indicated that scientific research and development in the field of inflammation is a very competitive field between research centers at the global level. He added that if the Arabian Gulf University is pioneering the discovery of a new inflammation marker, it shows that scientific ambition and perseverance can sometime compensate for the availability of an optimal research and development environment. However, at the innovation stage that should immediately follows the research and development phase and which produces socio-economic effects a special environment is essential. Lastly, Prof. Dahmani pointed out that in addition to the profound impact on our lives, the Corona pandemic has changed the scientific research environment, negatively as well as positively. As for the negative side, it lies in reducing the rate of direct communication between researchers and relying entirely on communication via electronic communication platforms, as well as the delay in receiving the materials needed to implement research. As for the positive perspective, it lies in increasing the scientific studies and the appreciation of the essential role of scientific research and intensive communication with civil society.

Send us your press releases to pressrelease.zawya@refinitiv.com

© Press Release 2021

Disclaimer: The contents of this press release was provided from an external third party provider. This website is not responsible for, and does not control, such external content. This content is provided on an “as is” and “as available” basis and has not been edited in any way. Neither this website nor our affiliates guarantee the accuracy of or endorse the views or opinions expressed in this press release.

The press release is provided for informational purposes only. The content does not provide tax, legal or investment advice or opinion regarding the suitability, value or profitability of any particular security, portfolio or investment strategy. Neither this website nor our affiliates shall be liable for any errors or inaccuracies in the content, or for any actions taken by you in reliance thereon. You expressly agree that your use of the information within this article is at your sole risk.

To the fullest extent permitted by applicable law, this website, its parent company, its subsidiaries, its affiliates and the respective shareholders, directors, officers, employees, agents, advertisers, content providers and licensors will not be liable (jointly or severally) to you for any direct, indirect, consequential, special, incidental, punitive or exemplary damages, including without limitation, lost profits, lost savings and lost revenues, whether in negligence, tort, contract or any other theory of liability, even if the parties have been advised of the possibility or could have foreseen any such damages.